Lupus & antiphospholipid syndrome
Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus
Authors' conclusion
Combining telitacicept with standard therapy induced significant changes in B cell subsets and clinical markers in SLE patients.
Study context
- Population
- Active systemic lupus erythematosus (SLE) patients (SLEDAI-2K ≥ 6)
- Participants
- 20 vs 21
- Exposure
- Telitacicept plus standard therapy, B cell subsets vs baseline
- Telitaciceptn = 20
- Healthy controlsn = 21reference
- Outcome
- Changes in detailed B cell subsets following telitacicept treatment
Methodological detailssingle-group, flow cytometry, B cell subsets and clinical assessments at 0, 4, 12 and 24 weeks
- Single-group
- Flow cytometry
- B cell subsets and clinical assessments at 0, 4, 12 and 24 weeks
Main finding
As reported in the abstract
B cell subsets vs baseline
- Decrease in total B cells
- p < 0.05
- Decreases in transitional B cells, naive B cells and short-lived plasma cells
- all p < 0.01
- Increase in proportion of B regulatory (Breg) cells
- p < 0.05
Observational data: associations, not effects.
Further findings
SRI-4 response · six months
- SRI-4 response rate (19/20)
- 95%
LLDAS achievement · six months
- Achievement of LLDAS (7/20)
- 35%
SLEDAI-2K scores and anti-dsDNA levels vs baseline
- Significant reductions (both p < 0.001)
Complement C3 and C4 levels vs baseline
- Increases (both p < 0.001)
24-h urine protein levels vs baseline
- Significant decrease (p = 0.004)
Original publication
Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus. Arthritis Res Ther. Published 18 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →